Infectious pulmonary complications in patients treated with anti-TNF-alpha monoclonal antibodies and soluble TNF receptor.
Tumor necrosis factor (TNF)-alpha inhibitors (infliximab, adalimumab, and etanercept) used in immune-mediated inflammatory diseases such as rheumatoid arthritis, Crohn's disease, or psoriatic arthritis have the potential to increase the risk of infectious complications. Pulmonary infections are one of the most frequent complications associated with the use of TNF inhibitors. This article provides an overview of the distinct types of infectious pulmonary complications seen in patients using these anticytokine drugs.
Clinical Immunology Unit, Immunology Department, University Hospital Gregorio Marañon, Dr Esquerdo 46, 28007, Madrid, Spain. jcarbone.hgugm@salud.madrid.org
Javier
J
Carbone
Javier
J
Perez-Rojas
Elizabeth
E
Sarmiento